Obsidian Therapeutics, Inc. (OBX) fair value analysis
Nasdaq · Updated 2026-10-19
OBX price how computed
Valuation status
No fair-value estimate yetOBX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for OBX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $11.77
- Sector
- Healthcare
- 12-month range
- $11.77–$18.99
- Market cap
- $727M
- From 52-week high
- -38.0%
- Shares outstanding
- 61.8M
- Rank in Healthcare by quality score
- #256 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Obsidian Therapeutics is a biotechnology company that develops immunology and regenerative medicine therapies. The company is based in the United States and operates in the healthcare sector.
OBX currently ranks #256 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $727M
- P/E (trailing)
- 0x
- EPS (TTM)
- $397.87
- Debt / equity
- 0.00
- Shares outstanding
- 61.8M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 27 · oversold
Earnings how computed
- Last 1 quarters vs consensus
- 1 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+27.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $39
- Target vs last price
- +231.4%
What our data shows for OBX
- Shares are trading in the lower third of their 12-month price range of $11.77–$18.99.
- The 14-day relative strength index sits at an oversold 27.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- OBX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the OBX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — OBX's relative strength index has moved into oversold territory this week, transitioning from a neutral zone where it stood previously. The healthcare sector indicator remains in an awaiting full valuation status, with this technical shift representing the only documented change in TickrTrends' derived indicators for the period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — OBX's relative strength index moved out of oversold territory into neutral zone this week, indicating a shift in momentum for the healthcare sector's short-term price action. The stock's valuation verdict remains awaiting full valuation, with no complete assessment currently available.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is OBX stock undervalued?
TickrTrends has no fair-value estimate for OBX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is OBX's TickrTrends verdict?
OBX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does OBX compare to other Healthcare stocks?
OBX ranks #256 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is OBX overbought or oversold?
OBX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does OBX usually beat earnings estimates?
Over its last 1 reported quarters OBX beat the consensus estimate 1 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about OBX?
Of 5 analysts covering OBX, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $39 (+231.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.